News

bit.bio outlines a transformative vision for drug discovery at The Human Cell Forum, emphasising the need for human cell-based mod...

bit.bio lowers ioCells pricing and opens EU hub with next-day delivery, expanding global access to human cells for NAMs research.

bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding...

bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability R...

bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepato...

Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.

Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...

Adding New Visualisation Functionality to Human iPSC-derived Cell Types